ERBB2 and breast carcinoma: Here, we investigated the role of HSP90 expression in the response of breast cancer cells to HER2-targeted treatments, using both preclinical cell line models and a mono-institutional series of metastatic, HER2+ breast cancer patients who underwent trastuzumab- or trastuzumab/pertuzumab-based first-line treatment.